These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
139 related articles for article (PubMed ID: 38950780)
1. A novel factor V compound heterozygous mutation associated with thrombosis (Y1961C; FV-Kanazawa, together with 1982_1983del). Shimonishi N; Morishita E; Ogiwara K; Maruyama K; Yoshida J; Horie K; Nogami K J Thromb Haemost; 2024 Jun; ():. PubMed ID: 38950780 [TBL] [Abstract][Full Text] [Related]
2. Impaired factor V-related anticoagulant mechanisms and deep vein thrombosis associated with A2086D and W1920R mutations. Shimonishi N; Ogiwara K; Yoshida J; Horie K; Nakajima Y; Furukawa S; Takeyama M; Nogami K Blood Adv; 2023 Jun; 7(12):2831-2842. PubMed ID: 36780344 [TBL] [Abstract][Full Text] [Related]
3. Novel FV mutation (W1920R, FVNara) associated with serious deep vein thrombosis and more potent APC resistance relative to FVLeiden. Nogami K; Shinozawa K; Ogiwara K; Matsumoto T; Amano K; Fukutake K; Shima M Blood; 2014 Apr; 123(15):2420-8. PubMed ID: 24523236 [TBL] [Abstract][Full Text] [Related]
4. Identification and functional characterization of a novel F5 mutation (Ala512Val, FVB onn ) associated with activated protein C resistance. Pezeshkpoor B; Castoldi E; Mahler A; Hanel D; Müller J; Hamedani NS; Biswas A; Oldenburg J; Pavlova A J Thromb Haemost; 2016 Jul; 14(7):1353-63. PubMed ID: 27090446 [TBL] [Abstract][Full Text] [Related]
5. Activated protein C resistance and thrombosis: molecular mechanisms of hypercoagulable state due to FVR506Q mutation. Dahlbäck B Semin Thromb Hemost; 1999; 25(3):273-89. PubMed ID: 10443959 [TBL] [Abstract][Full Text] [Related]
6. Factor V and thrombotic disease: description of a janus-faced protein. Nicolaes GA; Dahlbäck B Arterioscler Thromb Vasc Biol; 2002 Apr; 22(4):530-8. PubMed ID: 11950687 [TBL] [Abstract][Full Text] [Related]
7. Impaired APC cofactor activity of factor V plays a major role in the APC resistance associated with the factor V Leiden (R506Q) and R2 (H1299R) mutations. Castoldi E; Brugge JM; Nicolaes GA; Girelli D; Tans G; Rosing J Blood; 2004 Jun; 103(11):4173-9. PubMed ID: 14976057 [TBL] [Abstract][Full Text] [Related]
8. Activated protein C resistance: molecular mechanisms based on studies using purified Gln506-factor V. Heeb MJ; Kojima Y; Greengard JS; Griffin JH Blood; 1995 Jun; 85(12):3405-11. PubMed ID: 7780127 [TBL] [Abstract][Full Text] [Related]
9. Molecular mechanisms of activated protein C resistance. Properties of factor V isolated from an individual with homozygosity for the Arg506 to Gln mutation in the factor V gene. Aparicio C; Dahlbäck B Biochem J; 1996 Jan; 313 ( Pt 2)(Pt 2):467-72. PubMed ID: 8573079 [TBL] [Abstract][Full Text] [Related]
10. Anti-β2-glycoprotein I and anti-phosphatidylserine/prothrombin antibodies interfere with cleavage of factor V(a) by activated protein C. Noordermeer T; Chemlal S; Jansma JJ; van der Vegte V; Schutgens REG; Limper M; de Groot PG; Meijers JCM; Urbanus RT J Thromb Haemost; 2023 Sep; 21(9):2509-2518. PubMed ID: 37290588 [TBL] [Abstract][Full Text] [Related]
11. Severe thrombophilia in a factor V-deficient patient homozygous for the Ala2086Asp mutation (FV Besançon). Castoldi E; Hézard N; Mourey G; Wichapong K; Poggi M; Ibrahim-Kosta M; Thomassen MCLGD; Fournel A; Hayward CPM; Alessi MC; Hackeng TM; Rosing J; Morange PE J Thromb Haemost; 2021 May; 19(5):1186-1199. PubMed ID: 33605529 [TBL] [Abstract][Full Text] [Related]
12. Functional characterization of recombinant FV Hong Kong and FV Cambridge. Norstrøm E; Thorelli E; Dahlbäck B Blood; 2002 Jul; 100(2):524-30. PubMed ID: 12091344 [TBL] [Abstract][Full Text] [Related]
13. Factor V is an anticoagulant cofactor for activated protein C during inactivation of factor Va. Cramer TJ; Griffin JH; Gale AJ Pathophysiol Haemost Thromb; 2010; 37(1):17-23. PubMed ID: 20501981 [TBL] [Abstract][Full Text] [Related]
14. The second laminin G-type domain of protein S is indispensable for expression of full cofactor activity in activated protein C-catalysed inactivation of factor Va and factor VIIIa. Evenäs P; García de Frutos P; Nicolaes GA; Dahlbäck B Thromb Haemost; 2000 Aug; 84(2):271-7. PubMed ID: 10959700 [TBL] [Abstract][Full Text] [Related]
15. Carbohydrate moieties on the procofactor factor V, but not the derived cofactor factor Va, regulate its inactivation by activated protein C. Silveira JR; Kalafatis M; Tracy PB Biochemistry; 2002 Feb; 41(5):1672-80. PubMed ID: 11814362 [TBL] [Abstract][Full Text] [Related]
16. The anticoagulant function of coagulation factor V. Cramer TJ; Gale AJ Thromb Haemost; 2012 Jan; 107(1):15-21. PubMed ID: 22116556 [TBL] [Abstract][Full Text] [Related]
17. [Elucidation of an altered anticoagulant function due to Factor V abnormality and development of a simple screening assay for thrombophilia]. Shimonishi N; Nogami K Rinsho Ketsueki; 2023; 64(7):654-660. PubMed ID: 37544726 [TBL] [Abstract][Full Text] [Related]
18. The roles of factor Va and protein S in formation of the activated protein C/protein S/factor Va inactivation complex. Gierula M; Salles-Crawley II; Santamaria S; Teraz-Orosz A; Crawley JTB; Lane DA; Ahnström J J Thromb Haemost; 2019 Dec; 17(12):2056-2068. PubMed ID: 31364267 [TBL] [Abstract][Full Text] [Related]
19. Importance of individual activated protein C cleavage site regions in coagulation factor V for factor Va inactivation and for factor Xa activation. Heeb MJ; Rehemtulla A; Moussalli M; Kojima Y; Kaufman RJ Eur J Biochem; 1999 Feb; 260(1):64-75. PubMed ID: 10091585 [TBL] [Abstract][Full Text] [Related]
20. Coagulation function and mechanisms in various clinical phenotypes of patients with acquired factor V inhibitors. Matsumoto T; Nogami K; Shima M J Thromb Haemost; 2014 Sep; 12(9):1503-12. PubMed ID: 25041532 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]